AuraVax licenses intranasal vaccine platform

By The Science Advisory Board staff writers

October 12, 2020 -- Vaccine biotechnology firm AuraVax Therapeutics has entered into an exclusive licensing option agreement with the University of Houston for a unique intranasal vaccine technology.

The agreement allows AuraVax to exclusively license patents utilizing intellectual property related to the novel vaccine platform. The company intends to advance the technology to create vaccines that address multiple respiratory viruses, including SARS-CoV-2.

AuraVax is based out of Houston and was created by a professor at the University of Houston. The company's first goal is to create a more effective way to vaccinate against COVID-19.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.